Atlas Trials

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

Clinical trial NCT00626860 · COMPLETED

Trial details

NCT number
NCT00626860
Sponsor
Beth Israel Deaconess Medical Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Melanoma
Start date
2000-07-01
Primary completion
2002-01-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.